Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
A phase 3 trial of Saruparib, Camizestrant, Abemaciclib, Ribociclib, Palbociclib and Fulvestrant in HR-positive / HER2-negative breast cancer, run by AstraZeneca, now recruiting.
Overview
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer is a phase 3 interventional study registered as NCT06380751 by AstraZeneca, with 788 participants planned, started 2024-08-01 and due to reach its primary completion in 2029-12-18. Interventions recorded: Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib and Fulvestrant.
Similar pages
not linked directly; found by shared links- TrialCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
- TrialA Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Shares Camizestrant, Palbociclib, AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
- TrialA Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
Shares Camizestrant, Fulvestrant, AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Shares Camizestrant, Ribociclib, AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialStudy of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Shares Ribociclib, Abemaciclib, Palbociclib, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
- TrialDNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Shares Palbociclib, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.